StreetInsider.com News Articles

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

Mentari Therapeutics, Inc., a privately held biotechnology company focused on migraine prevention, announced a $200 million private placement consisting of common stock and pre-funded warrants, according to a press release dated July 22, 2026.

The financing round includes investors such as Fairmount, ADAR1 Capital Management, Venrock Healthcare Capital Partners, Janus Henderson Investors, Blackstone Multi-Asset Investing, RTW Investments, Deep Track Capital, BB Biotech, and others. Jefferies, TD Cowen, Stifel, and Guggenheim Securities acted as placement agents.

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics raises $200M in private placement tied to INM merger

Wed, 22 Jul 2026 07:00:28 -0400

The private placement is expected to close immediately before the completion of Mentari's planned merger with InMed Pharmaceuticals, Inc. (NASDAQ: INM) and concurrently with a previously announced

Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline